Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

Pinder SahotaDanish pharma group Novo Nordisk has appointed a new general manager and corporate vice president, UK, in the form of Pinder Sahota.

Sahota, who brings experience from business, commercial and leadership roles to Novo, was most recently responsible for creating commercial and market development strategies across Europe as senior vice president of market and commercial development for Europe at Smith & Nephew.

He said: “I am delighted to join Novo Nordisk in the role of general manager in the UK.

“The vision, values and passion that is immediately evident within the company makes Novo Nordisk and exciting organisation to be a part of.

“I look forward to working closely with my new colleagues with the aim of accelerating our business growth while positively impacting the healthcare ecosystem within which we operate, as well as supporting a positive internal culture and the development of strong talent at every level of our UK organisation.”

Sahota started his pharmaceutical career in sales and marketing with companies which formed Sanofi Aventis, before moving to SmithKline Beecham - now GlaxoSmithKline - where he held a number of commercial leadership roles including vice president of commercial operations of diabetes and cardiovascular.

In 2009 Sahota moved to AstraZeneca to assume the role of vice president for primary care in the UK, a position he held up until moving to the role of managing director for the UK and Ireland for Smith & Nephew in 2013.

Matt Regan, senior vice president, region Europe for Novo Nordisk, said: “Pinder’s extensive experience and knowledge will be a real strength as Novo Nordisk navigates the evolving UK landscape.”

12th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics